Uloga inflamatornih biomarkera RBP4, lipokalina-2 i hsCRP kod predijabetesa i dijabetes melitusa tipa 2
Inflammatory Biomarkers in Prediabetes
Sažetak
Background: Adipocytokines, along with macrophages infiltrating adipose tissue, contribute to chronic low-grade inflammation, which leads to insulin resistance and type 2 diabetes. Understanding insulin resistance in non-diabetic individuals and its cellular mechanisms is key for developing effective treatments and improving current protocols. This study aimed to investigate the levels of Retinol Binding Protein 4 (RBP4), Lipocalin-2, and high-sensitivity C-reactive protein (hsCRP) in individuals with impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and type 2 diabetes mellitus (T2DM).
Methods: This prospective case-control study study included individuals with IFG, IGT, and newly diagnosed T2DM. Routine laboratory tests, including fasting blood glucose, insulin, HbA1c, and lipid profiles, were collected and analyzed. RBP4, Lipocalin-2, and hsCRP levels were measured using the ELISA method.
Results: Significant differences were found in fasting blood glucose, insulin, triglycerides, total cholesterol, and HOMA-IR values among the study groups. hsCRP levels were significantly elevated in the IGT and T2DM groups compared to controls, while RBP4 and Lipocalin-2 levels showed no significant differences. A positive correlation was observed between hsCRP and HbA1c in the IFG group, as well as between hsCRP and Lipocalin-2 in the T2DM group.
Conclusion: This study demonstrates that hsCRP and Lipocalin-2 are associated with early glucose metabolism abnormalities and may serve as markers for insulin resistance and inflammation in prediabetes and T2DM. Future research is needed to clarify the roles of these biomarkers and their potential as therapeutic targets in diabetes prevention and treatment
Sva prava zadržana (c) 2025 OSMAN oğuz, Vesile Örnek Diker, Özden serin, Ebru Yorulmaz Ertuğ, Özlem Baytekin, Güvenç Güvenen
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.